Menu
Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 16
Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality – The STATUETTE Cohort Study [Corrigendum]
Authors Damkjær M, Håkansson K, Kallemose T , Ulrik CS , Godtfredsen N
Received 2 August 2021
Accepted for publication 2 August 2021
Published 19 August 2021 Volume 2021:16 Pages 2393—2395
Damkjær M, Håkansson K, Kallemose T, Ulrik CS, Godtfredsen N. Int J Chron Obstruct Pulmon Dis. 2021;16:579–589.
The authors have advised that the statistical analysis script incorrectly labelled patients receiving ICS/LABA-combination inhalers as only receiving LABA. The error has resulted in an incorrect prevalence of ICS treatment in Table 1 on page 583 (7% instead of the correct 55%) as well as some changes in regression covariable estimates in Table 2 on page 584. The correct Tables 1 and 2 are shown in Download Article.
Page 579, Abstract, Results section, the text “When stratifying for moderate and severe exacerbations in a sub-analysis in the same model, statin use did not have an increased HR for exacerbation of either severity (HR = 1.02 (95% CI 0.85 to 1.24; p = 0.811) and HR = 1.07 (95% CI 0.89 to 1.29; p = 0.492) respectively)” should read “When stratifying for moderate and severe exacerbations in a sub-analysis in the same model, statin use did not have an increased HR for exacerbation of either severity (HR = 1.02 (95% CI 0.85 to 1.23; p = 0.812) and HR = 1.07 (95% CI 0.89 to 1.29; p = 0.457) respectively)”.
Page 584, right column, second paragraph, the text “When stratifying for moderate and severe exacerbations in a sub-analysis in the same model, statin use was not to reduced time to AECOPD for either severity (HR = 1.02 (95% CI 0.85 to 1.24; p = 0.811) and HR = 1.07 (95% CI 0.89 to 1.29; p = 0.492) respectively)” should read “When stratifying for moderate and severe exacerbations in a sub-analysis in the same model, statin use was not to reduced time to AECOPD for either severity (HR = 1.02 (95% CI 0.85 to 1.23; p = 0.812) and HR = 1.07 (95% CI 0.89 to 1.29; p = 0.457) respectively)”.
The authors apologize for the error and advise the prevalence and regression analyses does not change the conclusions of the paper nor does it affect the presented main outcomes of the study.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.